Skip Navigation


JAC Advance Access originally published online on December 21, 2007
Journal of Antimicrobial Chemotherapy 2008 61(2):462-463; doi:10.1093/jac/dkm489
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
61/2/462    most recent
dkm489v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Palacios, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palacios, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

Minor emtricitabine intolerance in treatment-stable patients switched from tenofovir/lamivudine to a fixed-dose combination of tenofovir/emtricitabine (Truvada®)

Rosario Palacios1, Alberto Terrón2, Ana Hidalgo1, Antonio Rivero3, Jesús Santos on behalf of the SIMVA Group1,*,{dagger}

1 Hospital Virgen de la Victoria, Málaga, Spain 2 Hospital de Jerez, Spain 3 Hospital Reina Sofía, Córdoba, Spain

* Corresponding author. Tel: +34-951032594; Fax: +34-951032593; E-mail: med000854@saludalia.com

Keywords: antiretroviral therapy , adverse reactions , treatment

The first 10% of the full text of this article appears below.

Sir,

Emtricitabine 1 has characteristics similar to lamivudine with respect to activity, safety and resistance profile, and according to the current treatment guidelines, the two drugs are interchangeable.2 As the fixed-dose combination of emtricitabine and tenofovir was approved (Truvada®. . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?